Increased adherence to cardiac standards of care during participation in cardiac disease management programs

Disease Management

Volumn 11, Issue 2, 2008, Pages 111-118

  Coberley, Carter ^a   Morrow, Greg ^a   McGinnis, Matthew ^a   Wells, Aaron ^a   Coberley, Sadie ^a   Orr, Patty ^a   Shurney, Dexter ^a  

^a HEALTHWAYS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PIPEROCAINE;

ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; EVIDENCE BASED PRACTICE; FEMALE; HEALTH CARE QUALITY; HEALTH PROGRAM; HEART DISEASE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTICHOLESTEREMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; DISEASE MANAGEMENT; FEMALE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HEALTH STATUS INDICATORS; HEART FAILURE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PATIENT COMPLIANCE; PREVALENCE; RETROSPECTIVE STUDIES;

EID: 42649111686     PISSN: 1093507X     EISSN: None     Source Type: Journal    
DOI: 10.1089/dis.2008.112725     Document Type: Article

References (48)

1. Minino AM, Heron MP, Smith BL. Deaths: preliminary data for 2004. Natl Vital Stat Rep. 2006;54:1-49.
2. Rosamond W, Flegal K, Friday G, et al. Heart disease and stroke statistics - 2007 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2007;115:e69-e171.
3. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-897.
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
5. O'Keefe JH, Jr., Cordain L, Harris WH, Moe RM, Vogel R. Optimal low-density lipoprotein is 50 to 70 mg/dl: Lower is better and physiologically normal. J Am Coll Cardiol. 2004;43:2142-2146.
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA. 2004;291:1071-1080.
7. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
8. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
9. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495-1504.
10. Hunt SA. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol. 2005;46:e1-e82.
11. Sauls JL, Rone T. Emerging trends in the management of heart failure: Beta blocker therapy. Nurs Clin North Am. 2005;40:135-148.
12. Colucci WS, Packer M, Bristow MR, et al. Carvedilol inhibits clinical progression in patients with mild symptoms of heart failure. US Carvedilol Heart Failure Study Group. Circulation. 1996;94:2800-2806.
13. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001-2007.
14. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651-1658.
15. Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349-1355.
16. Erhardt L, MacLean A, Ilgenfritz J, Gelperin K, Blumenthal M. Fosinopril attenuates clinical deterioration and improves exercise tolerance in patients with heart failure. Fosinopril Efficacy/Safety Trial (FEST) Study Group. Eur Heart J. 1995;16:1892-1899.
17. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
18. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
19. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362:772-776.
20. Granger BB, Swedberg K, Ekman I, et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: Double-blind, randomised, controlled clinical trial. Lancet. 2005;366:2005-2011.
21. Sueta CA, Chowdhury M, Boccuzzi SJ, et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1999;83:1303-1307.
22. Sueta CA, Massing MW, Chowdhury M, Biggs DP, Simpson RJ, Jr. Undertreatment of hyperlipidemia in patients with coronary artery disease and heart failure. J Card Fail. 2003;9:36-41.
23. Luzier AB, DiTusa L. Underutilization of ACE inhibitors in heart failure. Pharmacotherapy. 1999;19:1296-1307.
24. Lee JK, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: A randomized controlled trial. JAMA. 2006;296:2563-2571.
25. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004;164:2343-2348.
26. Coberley C, McGinnis M, Orr P, et al. Association between frequency of telephonic contact and clinical testing for a large, geographically diverse diabetes disease management population. Dis Manag. 2007;10:101-109.
27. Twisk JWR. Applied Longitudinal Data Analysis for Epidemiology: A Practical Guide. Cambridge, UK: Cambridge University Press; 2003.
28. Carlsson L, Borjesson U, Edgren L. Patient-based "burden-of- illness" in Swedish primary health care. Applying the Johns Hopkins ACG case-mix system in a retrospective study of electronic patient records. Int J Health Plann Manag. 2002;17:269-282.
29. Coberley C, Hamar B, Gandy B, et al. Impact of telephonic interventions on glycosylated hemoglobin and low-density lipoprotein cholesterol testing. Am J Manag Care. 2007;13:31-35.
30. Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists' Collaboration. Lancet. 2000;356:1955-1964.
31. Chobanian AV. Can antihypertensive drugs reduce atherosclerosis and its clinical complications? Am J Hypertens. 1994;7:119S-125S.
32. Graninger M, Reiter R, Drucker C, Minar E, Jilma B. Angiotensin receptor blockade decreases markers of vascular inflammation. J Cardiovasc Pharmacol. 2004;44:335-339.
33. Thattassery E, Gheorghiade M. Beta blocker therapy after acute myocardial infarction in patients with heart failure and systolic dysfunction. Heart Fail Rev. 2004;9:107-113.
34. Cooper R, Cutler J, Desvigne-Nickens P, et al. Trends and disparities in coronary heart disease, stroke, and other cardiovascular diseases in the United States: Findings of the national conference on cardiovascular disease prevention. Circulation. 2000;102:3137-3147.
35. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation. 2005;111:499-510.
36. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
37. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.
38. Switzer JA, Hess DC. Statin therapy for coronary heart disease and its effect on stroke. Curr Atheroscler Rep. 2006;8:337-342.
39. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497.
40. Simpson RJ, Jr. Challenges for improving medication adherence. JAMA. 2006;296:2563-2571.
41. Smith SC, Jr., Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation. 2001;104:1577-1579.
42. Byrne M, Walsh J, Murphy AW. Secondary prevention of coronary heart disease: Patient beliefs and health-related behaviour. J Psychosom Res. 2005;58:403-415.
43. Sattar SP, Shakeel Ahmed M, Majeed F, Petty F. Inert medication ingredients causing nonadherence due to religious beliefs. Ann Pharmacother. 2004;38:621-624.
44. Spertus JA, Eagle KA, Krumholz HM, Mitchell KR, Normand SL. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. Circulation. 2005;111:1703-1712.
45. Fuster V, Smaha L. AHA's new strategic impact goal designed to curb epidemic of cardiovascular disease and stroke. Circulation. 1999;99:2360.
46. US Department of Health and Human Services. Healthy People 2010; Understanding and Improving Health. Available at: 〈www.healthypeople. gov〉. Accessed on January 15, 2008.
47. Goff DC, Jr., Brass L, Braun LT, et al. Essential features of a surveillance system to support the prevention and management of heart disease and stroke: A scientific statement from the American Heart Association Councils on Epidemiology and Prevention, Stroke, and Cardiovascular Nursing and the Interdisciplinary Working Groups on Quality of Care and Outcomes Research and Atherosclerotic Peripheral Vascular Disease. Circulation. 2007;115:127-155.
48. Orr P, Hobgood A, Coberley S, et al. Improvement of LDL-C laboratory values achieved by participation in a cardiac or diabetes disease management program. Dis Manag. 2006;9:360-370.